-+ 0.00%
-+ 0.00%
-+ 0.00%

ProKidney FY 2024 GAAP EPS $(0.62) Misses $(0.57) Estimate, Ended The Fourth Quarter With $358M In Cash And Cash Equivalents And Marketable Securities, Supporting Operations Into Mid-2027

Benzinga·03/17/2025 11:32:34
Listen to the news
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 8.77 percent decrease over losses of $(0.57) per share from the same period last year.